Literature DB >> 16963684

Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties.

Silvia Ulrich1, Manuel Fischler, Rudolf Speich, Vladimir Popov, Marco Maggiorini.   

Abstract

BACKGROUND: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are the major classes of pulmonary hypertensive disorders according to the World Health Organization; both lead to right heart failure and death. A better understanding of disease mechanisms has led to the suggestion that the thromboembolic and nonthromboembolic types of pulmonary hypertension may share pathophysiologic features. We therefore compared acute vasoreactivity and proximal pulmonary artery compliance in patients with PAH and CTEPH during the initial diagnostic heart catheterization.
METHODS: Right heart catheterization using a flow-directed Swan-Ganz catheter was performed in patients with CTEPH (n = 22) and PAH (n = 35). Pulmonary hemodynamics were assessed at baseline, during the inhalation of 40 ppm of nitric oxide, and 30 min after the inhalation of 10 mug of iloprost. To assess the proximal pulmonary artery compliance, the pulse pressure (PP) [systolic-diastolic pressure] and the fractional PP (PPf) [divided by the mean pressure] were calculated.
RESULTS: Both vasodilators produced similar hemodynamic improvement, and the difference between CTEPH and PAH was not significant. The baseline PP and PPf did not vary between the two groups.
CONCLUSION: Patients with PAH and CTEPH show similar acute vasoreactivity to inhaled nitric oxide and iloprost, and have similar pulmonary artery compliance. These findings support the presence of some shared pathophysiologic pathways in both disorders and may lead to therapeutic implications in patients with inoperable CTEPH.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16963684     DOI: 10.1378/chest.130.3.841

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

1.  Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension.

Authors:  Mark R Toshner; Deepa Gopalan; Jay Suntharalingam; Carmen Treacy; Elaine Soon; Karen K Sheares; Nicholas W Morrell; Nicholas Screaton; Joanna Pepke-Zaba
Journal:  J Heart Lung Transplant       Date:  2010-03-15       Impact factor: 10.247

2.  Clinical and haemodynamic evaluation of chronic thromboembolic pulmonary hypertension patients scheduled for pulmonary thromboendarterectomy: Is schistosomiasis hypertension an important confounding factor?

Authors:  Mario Terra-Filho; Marcos Figueiredo Mello; Mônica Silveira Lapa; Ricardo Henrique Oliveira Braga Teixeira; Fábio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

3.  Bosentan in pulmonary arterial hypertension: a comparison between congenital heart disease and chronic pulmonary embolism.

Authors:  M G J Duffels; M N van der Plas; S Surie; M M Winter; B Bouma; M Groenink; A P J van Dijk; E Hoendermis; R M F Berger; P Bresser; B J M Mulder
Journal:  Neth Heart J       Date:  2009-09       Impact factor: 2.380

4.  Changed hemodynamics in acute vasoreactivity testing: prognostic predictors in chronic thromboembolic pulmonary hypertension.

Authors:  Yan-Zhe Yu; Ping Yuan; Yi-Lan Yang; Yuan-Yuan Sun; Qin-Hua Zhao; Lan Wang; Rong Jiang; Wen-Hui Wu; Jing He; Jing-Hong Dai; Yuan Li; Bigyan Pudasaini; Jin-Ling Li; Su-Gang Gong; Wei-Ping Xie; Jin-Ming Liu
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

5.  Clinical Study of Acute Vasoreactivity Testing in Patients with Chronic Thromboembolic Pulmonary Hypertension.

Authors:  Qi-Xia Xu; Yuan-Hua Yang; Jie Geng; Zhen-Guo Zhai; Juan-Ni Gong; Ji-Feng Li; Xiao Tang; Chen Wang
Journal:  Chin Med J (Engl)       Date:  2017-02-20       Impact factor: 2.628

Review 6.  Evolution of randomized, controlled studies of medical therapy in chronic thromboembolic pulmonary hypertension.

Authors:  Nick H Kim; Demosthenes G Papamatheakis; Timothy M Fernandes
Journal:  Pulm Circ       Date:  2021-05-24       Impact factor: 3.017

7.  Prognostic significance of insulin resistance in pulmonary hypertension.

Authors:  Elahe Zare; Parvaneh Kafshbani; Maryam Chenaghlou; Mehdi Noori; Zahra Ghaemmaghami; Ahmad Amin; Sepideh Taghavi; Nasim Naderi
Journal:  ESC Heart Fail       Date:  2021-12-13

Review 8.  Comparative Efficacy and Safety of Targeted Therapies for Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Network Meta-Analysis.

Authors:  Yusi Chen; Fang Li; Jun Luo; Jingyuan Chen; Peng Luo; Jiang Li
Journal:  Can Respir J       Date:  2021-09-01       Impact factor: 2.409

Review 9.  Inhaled iloprost for the control of pulmonary hypertension.

Authors:  Sabine Krug; Armin Sablotzki; Stefan Hammerschmidt; Hubert Wirtz; Hans-Juergen Seyfarth
Journal:  Vasc Health Risk Manag       Date:  2009

10.  Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: 2014 updates.

Authors:  Majdy M Idrees; Sarfraz Saleemi; M Ali Azem; Saleh Aldammas; Manal Alhazmi; Javid Khan; Abdulgafour Gari; Maha Aldabbagh; Husam Sakkijha; Abdulla Aldalaan; Khalid Alnajashi; Waleed Alhabeeb; Imran Nizami; Amjad Kouatli; May Chehab; Omar Tamimi; Hanaa Banjar; Tarek Kashour; Antonio Lopes; Omar Minai; Paul Hassoun; Qadar Pasha; Eckhard Mayer; Ghazwan Butrous; Sastry Bhagavathula; Stefano Ghio; John Swiston; Adel Boueiz; Adriano Tonelli; Robert D Levy; Marius Hoeper; Rober D Levy
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.